HemoGenyx, LLC

HemoGenyx is a preclinical-stage biotechnology company focused on the discovery, development and commercialisation of novel therapies and treatments for blood diseases, like leukemia and lymphoma. HemoGenyx Team: Vladislav Sandler

Read More

Parkside Scientific

New York City based Parkside Scientific develops novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory disorders.   Parkside Scientific Team: Gary Duberstein

Read More

Lucerna, Inc.

At Lucerna, we are developing new sets of research tools to study and exploit RNA the same way fluorescent proteins did for the protein field. Lucerna Team: Karen Wu

Read More

Mirimus

Mirimus is engaged in the design, development and pioneering of new genome editing technologies to develop animal models that are crucial for the preclinical evaluation of new therapeutics. Mirimus Team: Prem Premsrirut    

Read More

Novyx Technologies

A cost-effective hydrogel dressing for chronic wounds, which enhances wound healing, reduces inflammation, risk of infection and pain, as well as provides comfort during use. Novyx Technologies Team: Waleed Abdel-Naby, PhD

Read More

Taithera, Inc.

Aithera is a revolutionary nanomedicine bone targeted drug delivery controlled release platform technology for the treatment of musculoskeletal conditions focused initially on fracture healing & bone cancer (osteosarcoma is our first oncology target). Aithera Team: Seth Harlem, CEO Mo Chen, PhD, CSO

Read More

Massive Bio

Massive Bio provides cutting-edge concierge advisory services for precision oncology to cancer patients treated at community practices. Massive Bio Team: Selin Kurnaz, PhD. – CEO

Read More

Jotteq

Jot is a new kind of eye drop dispenser that is safe and easy to use. My objective is to bring it to market Jotteq Team: Nigel Kelly

Read More

Ichor Biologics

A validated platform for the isolation of human monoclonal antibodies (mAbs), which neutralize emerging and re-emerging infectious diseases. Ichor Biologics Team: Raymond Alvarez Justin Ring

Read More